ClinicalTrials.gg
TerminatedNCT04382898PRO-MERITUpdated Mar 20, 2025Results posted

PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)

A Phase 1/2 interventional study of BNT112 and Cemiplimab in Prostate Cancer, sponsored by BioNTech SE. Terminated at 22 sites in 4 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-20.

Sponsored by BioNTech SE · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Sponsor decision

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Dec 2019, registered Apr 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 333 studies in Prostatic Neoplasms with a site in Germany — 71 open to participants now, 117 under way, 36 of them phase 3. Prostatic Neoplasms · Germany.

Enrollment
220th of 269
75 · median 278
Started
2019
with 18 others
Phase 1/2
13 of 333
8 open now
Registered
218th of 333
by date

Among the 333 studies in Prostatic Neoplasms with a site in Germany, this one is the 220th largest by enrollment of the 269 interventional ones that give a count, is one of 19 that started in 2019, is one of 13 in phase 1/2, and was the 218th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

71 of the 333 studies in Prostatic Neoplasms with a site in Germany are open now. Recruiting first, the newest first:

66 more — sign in →

All 71 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 333 studies in Prostatic Neoplasms with a site in Germany, or all of them as a file.
02

Study summary

Open-label, multicenter, dose titration and four-arm expansion trial to evaluate the safety, tolerability, immunogenicity, and preliminary efficacy of BNT112 cancer vaccine (BNT112) monotherapy or in combination with cemiplimab in patients with metastatic castration resistant prostate cancer (mCRPC: Part 1 and Part 2 Arms 1A and 1B) and in patients with high-risk, localized prostate cancer (LPC).

As of February 2023, the trial only recruited LPC patients and no longer mCRPC patients.

Read the detailed description
  • BNT112 consisted of messenger ribonucleic acid (mRNA [or RNA]) targeting 5 antigens expressed in de novo and metastatic prostate cancer that were separately complexed with liposomes to form serum-stable RNA lipoplexes (RNA-LPX).
  • The RNA molecules were immune-pharmacologically optimized for high stability, translational efficiency and presentation on major histocompatibility complex (MHC) class I and II molecules. The vaccine was intended for intravenous (IV) bolus injection.
  • The RNA-LPX cancer vaccine induced activation of both the adaptive immune system (vaccine antigen-specific CD8+/CD4+ T cell) as well as the innate immune system (TLR7 agonism of single-stranded RNA). The physiology of efficient induction, expansion and differentiation of antigen-specific T cells was associated with programmed death receptor-1 (PD-1) upregulation on these T cells. Thus, the cancer vaccine was expected to have a synergistic mechanism of action with anti-PD-1.
  • The step-up dose titration approach allowed for optimal dose management on an individual basis and accounted for inter- and intra-individual variability of the immune system.
  • In summary, the mechanism of action of BNT112 both in monotherapy and in combination with anti-PD-1 immune checkpoint inhibitor cemiplimab, together with carefully selected and refined clinical setting presented a unique opportunity for patients with different stages of prostate cancer.
03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Prostate cancer
  • PRO-MERIT
  • Cancer vaccine
  • W_pro1
  • BioNTech SE
  • RNA
  • mCRPC
  • LPC
  • Cemiplimab
  • BNT112
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria:

  • Patients were male and aged >=18 years.
  • Patients had confirmed prostate adenocarcinoma.
  • Patients had an Performance Status (ECOG PS) score of 0 or 1.

Specific key inclusion criteria for mCRPC patients (Part 1 and Part 2 Arms 1A and 1B) - Recruitment of mCRPC patients now completed:

  • Patients had histologically confirmed mCRPC and had progressed after at least 2 but no more than 3 lines of life-prolonging systemic therapy (e.g., abiraterone or enzalutamide, docetaxel, cabazitaxel) or cannot tolerate or refused any of these therapies. These included life-prolonging therapies administered in the hormone-sensitive setting.
  • Prior surgical or chemical castration with a serum testosterone \<1.7 nmol/L (50 ng/dL). If the method of castration was luteinizing hormone-releasing hormone analogue (LHRHa), there was a plan to maintain effective LHRHa therapy for the duration of the trial.
  • Patients had documented mCRPC progression within 6 months prior to screening (assuming no subsequent change in treatments), as determined by the investigator.
  • Patients agreed to provide an archival pre-treatment formalin-fixed, paraffin-embedded tumor sample if available.

Specific key inclusion criteria for newly diagnosed LPC patients (Part 2 Arms 2 and 3):

  • Treatment-naïve patients with LPC (i.e., N0, M0). According to risk levels of the European Association of Urology Guidelines on Prostate Cancer (2018), and in line with the U.S. National Comprehensive Cancer Network (NCCN 2020), patients had at least 1 of the following:

    1. PSA >20 ng/mL or
    2. Gleason Score >7 or
    3. Localized stage >=cT2c, N0, M0 according to tumor, node, metastasis classification.
  • Patients who intend to have and were suitable for a radical prostatectomy.
  • Patients agreed to provide tumor sample(s) from pre-treatment diagnostic and planned post-treatment surgery.

Main exclusion criteria for all patients:

Medical conditions

  • Patients with uncontrolled intercurrent illness.
  • Patients with a known history or current other than the inclusion diagnosis. Note: Exceptions were patients with malignancies with a negligible risk of metastasis or death, that had been adequately treated, such as non-invasive basal cell or non-invasive squamous cell skin carcinoma, non-invasive, superficial bladder cancer, and any cancer with a complete response (CR) that lasted more than 2 years might be included.
  • Patients who had major surgery (e.g., requiring general anesthesia) within 4 weeks before screening, or have not fully recovered from surgery, or had a surgery planned during the time of trial participation, except for the radical prostatectomy planned for patients in Part 2 Arms 2 and 3.
  • Patients who had a known history of any of the following:

    1. (HIV) 1 or 2
    2. (carrier or active infection)
    3. (unless considered cured 5 years post curative anti-viral therapy)
  • Patients who have received or currently receive the following therapy/treatment:

    1. Chronic systemic treatment (prednisone >5 mg daily orally [PO] or IV, or equivalent) during the trial. Note: Replacement therapy (e.g., physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is permitted.
    2. Prior treatment with other immune modulating agents that was (a) within fewer than 4 weeks (28 days) or 5 half-lives (whichever is longer) prior to the first dose of cemiplimab, or (b) associated with immune-mediated AEs that were Grade >=1 within 90 days prior to the first dose of cemiplimab, or (c) associated with toxicity that resulted in discontinuation of the immune-modulating agent.
    3. Prior treatment with other immune modulating agents for any non-cancer disease within 4 weeks or 5 half-lives of the agent (whichever is longer) before the first dose of IMP.
    4. Prior treatment with within 4 weeks before the first dose of IMP and during treatment with IMP.
    5. Prior treatment with an drug (including investigational vaccines) within 4 weeks or 5 half-lives of the agent (whichever is longer) before the planned first dose of IMP.
    6. Therapeutic PO or IV antibiotics within 14 days prior to enrollment. Note: Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or ) might be enrolled.
    7. Concurrent use of herbal products that might decrease PSA levels (e.g., saw palmetto).

Specific key exclusion criteria for mCRPC Patients (Part 1 and Part 2 Arms 1A and 1B) - Recruitment of mCRPC patients now completed:

Excluded medical conditions

  • Patients with toxicities from previous anti-cancer therapies that have not resolved to baseline levels or to Grade \<=1 according to National Cancer Institute (NCI) v5.0 with the exception of alopecia, anorexia, vitiligo, fatigue, hyperthyroidism, hypothyroidism, and peripheral neuropathy. Anorexia, hyperthyroidism, hypothyroidism, and peripheral neuropathy must have recovered to Grade \<=2.
  • Patients with clinically active .

    1. Patients with a history of symptomatic metastatic brain or meningeal tumors might be included, if the end of definitive therapy was >3 months before the first dose of BNT112 and the patients had no clinical or radiological evidence of tumor growth.
    2. Patients with brain metastases must not be undergoing acute or chronic corticosteroid therapy or steroid taper.
    3. Patients with central nervous system symptoms should undergo a computed tomography (CT) scan or magnetic resonance imaging (MRI) of the brain to exclude new or progressive brain metastases. Spinal cord metastasis is acceptable. However, patients with spinal cord compression should be excluded.

Excluded prior or concomitant anti-cancer therapies

  • Patients who received or currently receive the following anti-cancer therapy/agent:

    1. Prior radiation therapy with curative intent within 14 days before the first dose of IMP. Note: Palliative radiotherapy is allowed.
    2. Prior treatment with an anti-cancer agent (within 4 weeks or for systemic therapies after at least 5 half-lives of the drug [whichever is longer] before the first dose of IMP). Note: Prior treatment with bone resorptive therapy, such as bisphosphonates (e.g., pamidronate, zoledronic acid, etc.) and denosumab, is allowed assuming that the patients have been on stable doses for >=4 weeks prior to first dose of trial treatment.
    3. Prior treatment with anti-cancer immunomodulating agents, such as blockers of programmed death receptor-1 , programmed cell death 1 ligand 1 (PD-L1), tumor necrosis factor receptor superfamily member 9 (TNRSF9, 4-1BB, CD137), OX-40, therapeutic vaccines, cytokine treatments, or any investigational agent within 4 weeks or 5 half-lives (whichever was longer) before the first dose of IMP.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    Part 1 (mCRPC) - dose titration

    BNT112 monotherapy Enrollment into this arm is completed.

    Biological: BNT112

  • Experimental
    Part 2 Arm 1A (mCRPC) - expansion cohort

    BNT112 in combination with cemiplimab Enrollment into this arm is completed.

    Biological: BNT112 · Drug: Cemiplimab

  • Experimental
    Part 2 Arm 1B [1] (mCRPC) - expansion cohort

    BNT112 monotherapy Enrollment into this arm is completed.

    Biological: BNT112

  • Experimental
    Part 2 Arm 2 (LPC) - expansion cohort

    BNT112 in combination with cemiplimab

    Biological: BNT112 · Drug: Cemiplimab

  • Experimental
    Part 2 Arm 3 (LPC) - expansion cohort

    BNT112 monotherapy

    Biological: BNT112

  • Experimental
    Part 2 Arm 1B [2] (mCRPC) - expansion cohort

    Following progression after BNT112 monotherapy, patients in Arm 1b have the option to be treated with cemiplimab monotherapy Enrollment into this arm is completed.

    Drug: Cemiplimab

Interventions

  • BiologicalBNT112

    Intravenous bolus injection

  • Intravenous infusion

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)

    DLT criteria were defined as following: any treatment-emergent adverse events (TEAE) of Grade 5 intensity; hematological toxicities (Grade 3 and 4 febrile neutropenia, Grade 4 thrombocytopenia, Grade 3 and 4 hemorrhage associated with thrombocytopenia of Grade greater than or equal to \[\>=\] 3, Grade 4 anemia); and non-hematological toxicities (Grade 4 cytokine release syndrome \[CRS\], Grade 3 CRS which has not improved to Grade 1 or resolved within 48 hours; any Grade \>=3 non-hematological TEAE at least possibly related which occurs during the first BNT112 cancer vaccine treatment cycle).

    Time frame: Cycle 1 (21 days)

  2. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Related to Trial Procedure

    TEAE: any adverse event (AE) with an onset date on or after the first administration of investigational medicinal product (IMP) or worsened after first administration of IMP. AEs with an onset date more than 30 days after last dose of BNT112 or 90 days after last dose of cemiplimab (for Part 2, Arm 1a and Arm 2) were only considered as TEAEs if assessed as related to IMP by the investigator. Serious adverse event (SAE): any untoward medical occurrence that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect or was another medically important condition. AEs were graded for severity using National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI-CTCAE v5.0), where Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4 - Life-threatening consequences; Grade 5: Death related to AE.

    Time frame: From Baseline up to 30 days after the last dose of BNT112 (for Part 1 and Part 2 Arms 1b and 3) or up to 90 days after the last dose of cemiplimab (for Part 2, Arm 1a and Arm 2) (up to 4 years and 1 month)

  3. Part 2 Arm 1a: Objective Response Rate (ORR)

    ORR was defined as the percentage of participants with a complete response (CR) or partial response (PR) as per Prostate Cancer Working Group 3 (PCWG3) criteria as determined by the investigator. Participants not meeting the criteria for CR or PR, including those without any post-baseline tumor assessments, were considered as non-responders. CR was defined as the disappearance of all target lesions, with a reduction in short axis to \<10 mm in any pathological lymph nodes and no new lesions. PR was defined as 30% decrease in the sum of the longest diameter of target lesions.

    Time frame: From start of treatment up to 46 weeks

  4. Part 2 Arm 1b: Objective Response Rate (ORR)

    ORR was defined as the percentage of participants with a CR or PR as per PCWG3 criteria as determined by the investigator. Participants not meeting the criteria for CR or PR, including those without any post-baseline tumor assessments, were considered as non-responders. CR was defined as the disappearance of all target lesions, with a reduction in short axis to \<10 mm in any pathological lymph nodes and no new lesions. PR was defined as 30% decrease in the sum of the longest diameter of target lesions.

    Time frame: From start of treatment up to 104 weeks

Secondary outcomes

  1. Number of Participants Reporting Change From Baseline in Prostate-specific Antigen (PSA) Levels

    Participants blood samples were tested for levels of PSA to track the progression of prostate cancer. PSA decline categories of No decline, 0 to 25%, \>25% to 50%, and \>50% compared to baseline during treatment according to PCWG3 (as reported by the investigator) are reported in this outcome measure. EOT in the timeframe below refers to End of treatment.

    Time frame: Day8 (Cycles1&2 only), Day1 Cycle 2 & Day 15 (Cycles1,2 & 8 only) (each cycle of 21-days), & EOT (30 days after last dose of BNT112 [Part 1 & Part 2 Arms 1b & 3] or 90 days after last dose of cemiplimab [Part 2, Arm 1a & Arm 2] [up to 4 years & 1 months])

  2. Number of Participants Reporting Change From Baseline in PSA Doubling Time (PSADT)

    Participants blood samples were tested for levels of PSA to track the progression of prostate cancer. PSADT was calculated using a linear regression model of the natural logarithm of PSA values and time. PSA doubling time compared to baseline during the treatment period for the following categories: 0 - 3 months; \>3 - 6 months; \>6 - 9 months; \>9 - 12 months; \>12 - 18 months; \>18 - 24 months; \>24 months and declining are reported in this outcome measure.

    Time frame: Cycle 4 Day 1, Cycle 8 Day 1, Cycle 12 Day 1 (each cycle duration=21 days)

  3. Number of Participants With PSA Decline of >=50%

    Participants blood samples were tested for levels of PSA to track the progression of prostate cancer. Participants with PSA decline of \>=50% compared to baseline according to PCWG3 (as reported by the investigator) are reported in this outcome measure. EOT in the timeframe below refers to End of treatment.

    Time frame: Day8 (Cycles1&2 only), Day1 Cycle 2 & Day 15 (Cycles1,2 & 8 only) (each cycle of 21-days), & EOT (30 days after last dose of BNT112 [Part 1 & Part 2 Arms 1b & 3] or 90 days after last dose of cemiplimab [Part 2, Arm 1a & Arm 2] [up to 4 years & 1 months])

  4. Part 1: Objective Response Rate (ORR)

    ORR was defined as the percentage of participants with a CR or PR as per PCWG3 criteria as determined by the investigator. Participants not meeting the criteria for CR or PR, including those without any post-baseline tumor assessments, were considered as non-responders. CR was defined as the disappearance of all target lesions, with a reduction in short axis to \<10 mm in any pathological lymph nodes and no new lesions. PR was defined as 30% decrease in the sum of the longest diameter of target lesions.

    Time frame: From start of treatment up to 27 weeks

  5. Part 2: Arms 2 and 3: Number of Participants With Tumor Response Post-Treatment

    The best overall response was defined as a single best response status at any tumor response assessment after first administration of IMP and prior to or at the start date of the first subsequent anti-cancer therapy. Overall response of progressive disease within 14 days after the start date of first subsequent anti-cancer therapy was considered. The following order of tumor response categories were used, where "Complete Response" is the best category: Complete Response (CR) - Partial Response (PR) - Stable Disease (SD) - Progressive Disease (PD) - Not Evaluable (NE) - Missing. CR: disappearance of all target lesions, with reduction in short axis to \<10 mm in any pathological lymph nodes and no new lesions. PR:30% decrease in the sum of the longest diameter of target lesions. PD: progression of target lesions (sum of diameter increase to nadir of \>=20% and by \>=5 mm), progression of existing non-target lesions, or appearance of 1 or more new lesions.SD: no evidence of PD, CR or PR.

    Time frame: From start of treatment up to 25 weeks (Arm 2) and up to 26 weeks (Arm 3)

07

Results

Posted Mar 20, 2025

Participant flow

The trial consisted of 2 parts: Part 1 (dose titration) and Part 2 (dose expansion; consisted of four arms).

Part 1: Dose Titration
Participant flow — Part 1: Dose Titration
MilestonePart 1 (mCRPC): BNT112Part 2 (mCRPC): Arm 1a: BNT112 + CemiplimabPart 2 (mCRPC): Arm 1b: BNT112Part 2 (LPC): Arm 2: BNT112 + CemiplimabPart 2 (LPC): Arm 3: BNT112
Started90000
Completed20000
Not completed70000
Withdrew: Withdrawal by subject10000
Withdrew: Death60000
Part 2: Dose Expansion
Participant flow — Part 2: Dose Expansion
MilestonePart 1 (mCRPC): BNT112Part 2 (mCRPC): Arm 1a: BNT112 + CemiplimabPart 2 (mCRPC): Arm 1b: BNT112Part 2 (LPC): Arm 2: BNT112 + CemiplimabPart 2 (LPC): Arm 3: BNT112
Started0282756
Completed010945
Not completed0181811
Withdrew: Withdrawal by subject00100
Withdrew: Lost to follow-up00100
Withdrew: Death0171310
Withdrew: Progressive disease00100
Withdrew: Study terminated by sponsor01101
Withdrew: Other00100

Outcome measures

PrimaryPart 1: Number of Participants With Dose Limiting Toxicities (DLTs)

DLT criteria were defined as following: any treatment-emergent adverse events (TEAE) of Grade 5 intensity; hematological toxicities (Grade 3 and 4 febrile neutropenia, Grade 4 thrombocytopenia, Grade 3 and 4 hemorrhage associated with thrombocytopenia of Grade greater than or equal to \[\>=\] 3, Grade 4 anemia); and non-hematological toxicities (Grade 4 cytokine release syndrome \[CRS\], Grade 3 CRS which has not improved to Grade 1 or resolved within 48 hours; any Grade \>=3 non-hematological TEAE at least possibly related which occurs during the first BNT112 cancer vaccine treatment cycle).

Time frame:
Cycle 1 (21 days)
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)
ParticipantsPart 1 (mCRPC): BNT112
Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)2
PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Related to Trial Procedure

TEAE: any adverse event (AE) with an onset date on or after the first administration of investigational medicinal product (IMP) or worsened after first administration of IMP. AEs with an onset date more than 30 days after last dose of BNT112 or 90 days after last dose of cemiplimab (for Part 2, Arm 1a and Arm 2) were only considered as TEAEs if assessed as related to IMP by the investigator. Serious adverse event (SAE): any untoward medical occurrence that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect or was another medically important condition. AEs were graded for severity using National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI-CTCAE v5.0), where Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4 - Life-threatening consequences; Grade 5: Death related to AE.

Time frame:
From Baseline up to 30 days after the last dose of BNT112 (for Part 1 and Part 2 Arms 1b and 3) or up to 90 days after the last dose of cemiplimab (for Part 2, Arm 1a and Arm 2) (up to 4 years and 1 month)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Related to Trial Procedure
ParticipantsPart 1 (mCRPC): BNT112Part 2 (mCRPC): Arm 1a: BNT112 + CemiplimabPart 2 (mCRPC): Arm 1b: BNT112Part 2 (LPC): Arm 2: BNT112 + CemiplimabPart 2 (LPC): Arm 3: BNT112
TEAEs8282656
Serious TEAE55922
Grade >= 3 TEAEs7151514
Grade 5 TEAEs20100
TEAEs related to trial procedure11012
PrimaryPart 2 Arm 1a: Objective Response Rate (ORR)

ORR was defined as the percentage of participants with a complete response (CR) or partial response (PR) as per Prostate Cancer Working Group 3 (PCWG3) criteria as determined by the investigator. Participants not meeting the criteria for CR or PR, including those without any post-baseline tumor assessments, were considered as non-responders. CR was defined as the disappearance of all target lesions, with a reduction in short axis to \<10 mm in any pathological lymph nodes and no new lesions. PR was defined as 30% decrease in the sum of the longest diameter of target lesions.

Time frame:
From start of treatment up to 46 weeks
Reported as:
Number · percentage of participants
Part 2 Arm 1a: Objective Response Rate (ORR)
percentage of participantsPart 2 (mCRPC): Arm 1a: BNT112 + Cemiplimab
Part 2 Arm 1a: Objective Response Rate (ORR)0 (0.0 to 12.8)
Statistical analysis
  • Part 2 (mCRPC): Arm 1a: BNT112 + Cemiplimab · Fisher Exact · p = 0.1041
SecondaryNumber of Participants Reporting Change From Baseline in Prostate-specific Antigen (PSA) Levels

Participants blood samples were tested for levels of PSA to track the progression of prostate cancer. PSA decline categories of No decline, 0 to 25%, \>25% to 50%, and \>50% compared to baseline during treatment according to PCWG3 (as reported by the investigator) are reported in this outcome measure. EOT in the timeframe below refers to End of treatment.

Time frame:
Day8 (Cycles1&2 only), Day1 Cycle 2 & Day 15 (Cycles1,2 & 8 only) (each cycle of 21-days), & EOT (30 days after last dose of BNT112 [Part 1 & Part 2 Arms 1b & 3] or 90 days after last dose of cemiplimab [Part 2, Arm 1a & Arm 2] [up to 4 years & 1 months])
Reported as:
Count of participants · Participants
Number of Participants Reporting Change From Baseline in Prostate-specific Antigen (PSA) Levels
ParticipantsPart 1 (mCRPC): BNT112Part 2 (mCRPC): Arm 1a: BNT112 + CemiplimabPart 2 (mCRPC): Arm 1b: BNT112Part 2 (LPC): Arm 2: BNT112 + CemiplimabPart 2 (LPC): Arm 3: BNT112
Cycle 1 Day 8: No decline————1
Cycle 1 Day 8: 0 to 25%————0
Cycle 1 Day 8: Greater than (>) 25% to 50%————0
Cycle 1 Day 8: >50%————0
Cycle 1 Day 15: No decline————0
Cycle 1 Day 15: 0 to 25%————0
Cycle 1 Day 15: >25% to 50%————1
Cycle 1 Day 15: >50%————0
Cycle 2 Day 1: No decline6211910
Cycle 2 Day 1: 0 to 25%23211
Cycle 2 Day 1: Greater than (>) 25% to 50%00101
Cycle 2 Day 1: >50%00134
Cycle 2 Day 8: No decline1———0
Cycle 2 Day 8: 0 to 25%0———0
Cycle 2 Day 8: > 25% to 50%0———0
Cycle 2 Day 8: >50%0———1
Cycle 2 Day 15: No decline————0
Cycle 2 Day 15: 0 to 25%————0
Cycle 2 Day 15: > 25% to 50%————0
Cycle 2 Day 15: >50%————1
Cycle 8 Day 15: No decline——1——
Cycle 8 Day 15: 0 to 25%——0——
Cycle 8 Day 15: > 25% to 50%——0——
Cycle 8 Day 15: >50%——0——
EOT: No decline7171900
EOT: 0 to 25%02000
EOT: > 25% to 50%00000
EOT: >50%00043
SecondaryNumber of Participants Reporting Change From Baseline in PSA Doubling Time (PSADT)

Participants blood samples were tested for levels of PSA to track the progression of prostate cancer. PSADT was calculated using a linear regression model of the natural logarithm of PSA values and time. PSA doubling time compared to baseline during the treatment period for the following categories: 0 - 3 months; \>3 - 6 months; \>6 - 9 months; \>9 - 12 months; \>12 - 18 months; \>18 - 24 months; \>24 months and declining are reported in this outcome measure.

Time frame:
Cycle 4 Day 1, Cycle 8 Day 1, Cycle 12 Day 1 (each cycle duration=21 days)
Reported as:
Count of participants · Participants
Number of Participants Reporting Change From Baseline in PSA Doubling Time (PSADT)
ParticipantsPart 1 (mCRPC): BNT112Part 2 (mCRPC): Arm 1a: BNT112 + CemiplimabPart 2 (mCRPC): Arm 1b: BNT112Part 2 (LPC): Arm 2: BNT112 + CemiplimabPart 2 (LPC): Arm 3: BNT112
Cycle 4 Day 1: 0 - 3 months5161110
Cycle 4 Day 1: >3 - 6 months02200
Cycle 4 Day 1: >6 - 9 months11200
Cycle 4 Day 1: >9 - 12 months00000
Cycle 4 Day 1: >12 - 18 months00000
Cycle 4 Day 1: >18 - 24 months00100
Cycle 4 Day 1: >24 months00000
Cycle 4 Day 1: Declining02345
Cycle 8 Day 1: 0 - 3 months36800
Cycle 8 Day 1: >3 - 6 months05100
Cycle 8 Day 1: >6 - 9 months01000
Cycle 8 Day 1: >9 - 12 months00200
Cycle 8 Day 1: >12 - 18 months00100
Cycle 8 Day 1: >18 - 24 months00000
Cycle 8 Day 1: > 24 months10100
Cycle 8 Day 1: Declining01256
Cycle 12 Day 1: 0 - 3 months32000
Cycle 12 Day 1: >3 - 6 months03100
Cycle 12 Day 1: >6 - 9 months01200
Cycle 12 Day 1: >9 - 12 months00100
Cycle 12 Day 1: >12 - 18 months00000
Cycle 12 Day 1: >18 - 24 months00000
Cycle 12 Day 1: > 24 months00000
Cycle 12 Day 1: Declining01243
SecondaryNumber of Participants With PSA Decline of >=50%

Participants blood samples were tested for levels of PSA to track the progression of prostate cancer. Participants with PSA decline of \>=50% compared to baseline according to PCWG3 (as reported by the investigator) are reported in this outcome measure. EOT in the timeframe below refers to End of treatment.

Time frame:
Day8 (Cycles1&2 only), Day1 Cycle 2 & Day 15 (Cycles1,2 & 8 only) (each cycle of 21-days), & EOT (30 days after last dose of BNT112 [Part 1 & Part 2 Arms 1b & 3] or 90 days after last dose of cemiplimab [Part 2, Arm 1a & Arm 2] [up to 4 years & 1 months])
Reported as:
Count of participants · Participants
Number of Participants With PSA Decline of >=50%
ParticipantsPart 1 (mCRPC): BNT112Part 2 (mCRPC): Arm 1a: BNT112 + CemiplimabPart 2 (mCRPC): Arm 1b: BNT112Part 2 (LPC): Arm 2: BNT112 + CemiplimabPart 2 (LPC): Arm 3: BNT112
Cycle 1 Day 8————0
Cycle 1 Day 15————0
Cycle 2 Day 100134
Cycle 2 Day 80———1
Cycle 2 Day 15————1
Cycle 8 Day 15——0——
EOT00043
SecondaryPart 1: Objective Response Rate (ORR)

ORR was defined as the percentage of participants with a CR or PR as per PCWG3 criteria as determined by the investigator. Participants not meeting the criteria for CR or PR, including those without any post-baseline tumor assessments, were considered as non-responders. CR was defined as the disappearance of all target lesions, with a reduction in short axis to \<10 mm in any pathological lymph nodes and no new lesions. PR was defined as 30% decrease in the sum of the longest diameter of target lesions.

Time frame:
From start of treatment up to 27 weeks
Reported as:
Number · percentage of participants
Part 1: Objective Response Rate (ORR)
percentage of participantsPart 1 (mCRPC): BNT112
Part 1: Objective Response Rate (ORR)0 (0.0 to 33.6)
SecondaryPart 2: Arms 2 and 3: Number of Participants With Tumor Response Post-Treatment

The best overall response was defined as a single best response status at any tumor response assessment after first administration of IMP and prior to or at the start date of the first subsequent anti-cancer therapy. Overall response of progressive disease within 14 days after the start date of first subsequent anti-cancer therapy was considered. The following order of tumor response categories were used, where "Complete Response" is the best category: Complete Response (CR) - Partial Response (PR) - Stable Disease (SD) - Progressive Disease (PD) - Not Evaluable (NE) - Missing. CR: disappearance of all target lesions, with reduction in short axis to \<10 mm in any pathological lymph nodes and no new lesions. PR:30% decrease in the sum of the longest diameter of target lesions. PD: progression of target lesions (sum of diameter increase to nadir of \>=20% and by \>=5 mm), progression of existing non-target lesions, or appearance of 1 or more new lesions.SD: no evidence of PD, CR or PR.

Time frame:
From start of treatment up to 25 weeks (Arm 2) and up to 26 weeks (Arm 3)
Reported as:
Count of participants · Participants
Part 2: Arms 2 and 3: Number of Participants With Tumor Response Post-Treatment
ParticipantsPart 2 (LPC): Arm 2: BNT112 + CemiplimabPart 2 (LPC): Arm 3: BNT112
Complete Response (CR)00
Partial Response (PR)33
Stable Disease (SD)22
Progressive Disease (PD)00
Not Evaluable (NE)00
Missing01
PrimaryPart 2 Arm 1b: Objective Response Rate (ORR)

ORR was defined as the percentage of participants with a CR or PR as per PCWG3 criteria as determined by the investigator. Participants not meeting the criteria for CR or PR, including those without any post-baseline tumor assessments, were considered as non-responders. CR was defined as the disappearance of all target lesions, with a reduction in short axis to \<10 mm in any pathological lymph nodes and no new lesions. PR was defined as 30% decrease in the sum of the longest diameter of target lesions.

Time frame:
From start of treatment up to 104 weeks
Reported as:
Number · percentage of participants
Part 2 Arm 1b: Objective Response Rate (ORR)
percentage of participantsPart 2 (mCRPC): Arm 1b: BNT112
Part 2 Arm 1b: Objective Response Rate (ORR)12.0 (2.5 to 31.2)
Statistical analysis
  • Part 2 (mCRPC): Arm 1b: BNT112 · Binomial test · p = 0.0541

Adverse events

Collected over From Baseline up to 30 days after the last dose of BNT112 (for Part 1 and Part 2 Arm 1b and 3) or up to 90 days after the last dose of cemiplimab (for Part 2, Arm 1a and Arm 2) (up to 4 years and 1 month). As per the protocol, non-SAEs with an onset date more than 30 days after the last dose of BNT112 or 90 days after the last dose of cemiplimab (for Part 2, Arm 1a and Arm 2) are only reported below if assessed as related to IMP by the investigator.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1 (mCRPC): BNT1127/9 (77.8%)5/9 (55.6%)8/9 (88.9%)
Part 2 (mCRPC): Arm 1a: BNT112 + Cemiplimab17/28 (60.7%)5/28 (17.9%)28/28 (100%)
Part 2 (mCRPC): Arm 1b: BNT11213/27 (48.1%)9/27 (33.3%)26/27 (96.3%)
Part 2 (LPC): Arm 2: BNT112 + Cemiplimab1/5 (20%)2/5 (40%)5/5 (100%)
Part 2 (LPC): Arm 3: BNT1120/6 (0%)2/6 (33.3%)6/6 (100%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventPart 1 (mCRPC): BNT112Part 2 (mCRPC): Arm 1a: BNT112 + CemiplimabPart 2 (mCRPC): Arm 1b: BNT112Part 2 (LPC): Arm 2: BNT112 + CemiplimabPart 2 (LPC): Arm 3: BNT112
AnaemiaBlood and lymphatic system disorders2/91/280/270/50/6
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/90/280/270/50/6
IleusGastrointestinal disorders0/90/280/271/51/6
Diabetic ketoacidosisMetabolism and nutrition disorders0/90/280/271/50/6
TinnitusEar and labyrinth disorders0/90/280/270/51/6
ParaesthesiaNervous system disorders0/90/280/270/51/6
HypertensionVascular disorders0/90/280/270/51/6
ThrombocytopeniaBlood and lymphatic system disorders1/90/280/270/50/6
Abdominal painGastrointestinal disorders1/90/280/270/50/6
NauseaGastrointestinal disorders1/90/280/270/50/6
Most frequent other events
Showing 10 of 86
Most frequent other events
EventPart 1 (mCRPC): BNT112Part 2 (mCRPC): Arm 1a: BNT112 + CemiplimabPart 2 (mCRPC): Arm 1b: BNT112Part 2 (LPC): Arm 2: BNT112 + CemiplimabPart 2 (LPC): Arm 3: BNT112
ChillsGeneral disorders1/916/286/271/54/6
PyrexiaGeneral disorders6/917/2816/271/52/6
Influenza like illnessGeneral disorders2/95/285/273/52/6
HypertensionVascular disorders4/94/285/271/53/6
AnaemiaBlood and lymphatic system disorders4/98/284/270/50/6
NauseaGastrointestinal disorders4/96/286/271/51/6
HeadacheNervous system disorders1/93/282/272/52/6
Urinary incontinenceRenal and urinary disorders0/91/280/272/50/6
FatigueGeneral disorders2/910/285/271/52/6
DiarrhoeaGastrointestinal disorders1/92/286/270/52/6

Baseline characteristics

Analysis was performed on Intent to Treat (ITT) population that included all participants who were randomized to the investigational medicinal product (IMP).

Age, Customized
Age, Customized(Participants)Part 1 (mCRPC): BNT112Part 2 (mCRPC): Arm 1a: BNT112 + CemiplimabPart 2 (mCRPC): Arm 1b: BNT112Part 2 (LPC): Arm 2: BNT112 + CemiplimabPart 2 (LPC): Arm 3: BNT112Total
< 50 years000000
>= 50 - < 65 years17113426
>= 65 - < 85 years820162248
>= 85 years010001
Sex: Female, Male
Sex: Female, Male(Participants)Part 1 (mCRPC): BNT112Part 2 (mCRPC): Arm 1a: BNT112 + CemiplimabPart 2 (mCRPC): Arm 1b: BNT112Part 2 (LPC): Arm 2: BNT112 + CemiplimabPart 2 (LPC): Arm 3: BNT112Total
Female000000
Male928275675
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1 (mCRPC): BNT112Part 2 (mCRPC): Arm 1a: BNT112 + CemiplimabPart 2 (mCRPC): Arm 1b: BNT112Part 2 (LPC): Arm 2: BNT112 + CemiplimabPart 2 (LPC): Arm 3: BNT112Total
Hispanic or Latino040004
Not Hispanic or Latino923274669
Unknown or Not Reported010102
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1 (mCRPC): BNT112Part 2 (mCRPC): Arm 1a: BNT112 + CemiplimabPart 2 (mCRPC): Arm 1b: BNT112Part 2 (LPC): Arm 2: BNT112 + CemiplimabPart 2 (LPC): Arm 3: BNT112Total
American Indian or Alaska Native000000
Asian100001
Native Hawaiian or Other Pacific Islander000000
Black or African American011215
White827263569
More than one race000000
Unknown or Not Reported000000
08

Study locations

22 sites
  • The University of Arizona Cancer Center
    Tucson, Arizona 85724, United States
  • University of Miami Hospital & Clinics /Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • University of Pittsburgh Cancer Inst.
    Pittsburgh, Pennsylvania 15215, United States
  • Urology San Antonio P.A.
    San Antonio, Texas 78229, United States
  • University of Virginia Cancer Center
    Charlottesville, Virginia 22908, United States
  • Universitätsklinikum Bonn
    Bonn, 53105, Germany
  • Klinikum der Johann Wolfgang Goethe-Universität
    Frankfurt, 60590, Germany
  • Universitätsklinikum Münster
    Münster, 48149, Germany
  • Studienpraxis Urologie
    Nürtingen, 72622, Germany
  • Urologische Klinik Planegg
    Planegg, 82152, Germany
  • Universitätsklinikum Tübingen
    Tübingen, 72076, Germany
  • Magyar Honvédség Egészségügyi Központ (MH EK Honvédkórház)
    Budapest, 1062, Hungary
  • Semmelweis Egyetem, Belgyógyászati Klinika
    Budapest, 1083, Hungary
  • Onkológiai Klinika
    Debrecen, 4032, Hungary
  • Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókórház
    Nyíregyháza, 4400, Hungary
  • Szent Borbála Kórház
    Tatabánya, 2800, Hungary
  • Cancer Research UK Cambridge Centre
    Cambridge, CB2 0RE, United Kingdom
  • Velindre Cancer Centre (VCC)
    Cardiff, CF14 2TL, United Kingdom
  • University of Glasgow, Beatson WoS Cancer Centre
    Glasgow, G12 0YN, United Kingdom
  • University College London Hospitals
    London, NW1 2PG, United Kingdom
  • The Royal Marsden Hospital
    London, SW3 6JJ, United Kingdom
  • University Hospital Southampton - Southampton General Hospital
    Southampton, SO16 6YD, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2019 to primary completion in Jan 2024, 49 months.

Results were first posted in Mar 2025, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2020
First posted
May 11, 2020
StartActual
Dec 19, 2019
Primary completionActual
Jan 23, 2024
CompletionActual
Jan 23, 2024
Results first posted
Mar 20, 2025
Last update
Mar 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04382898
Lead sponsor
BioNTech SE
Responsible party
Sponsor
First posted
May 11, 2020
Start date
Dec 19, 2019
Primary completion
Jan 23, 2024
Completion
Jan 23, 2024
Results posted
Mar 20, 2025
Last update
Mar 20, 2025

Study contacts

BioNTech Responsible Person
study director · BioNTech SE

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cemiplimab

Start the discussion